Q32 Bio Inc.

-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 -- -- Robust durability, including maintenance and deepening of response, observed following the 16-week off-drug period supporting potential for less frequent, chronic maintenance dosing -- -- Mechanism of action supported by biomarker results and biopsy findings -- -- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals -- -- Data supports further development of bempikibart as a chronic treatment in alopecia areata; Q32 Bio intends to advance a registration-directed program in the first half of 2027 -- WALTHAM, Mass., Sept. 30, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA.

Q32 Bio'S bempikibart could offer lasting hair regrowth in alopecia areata, but its potential advantage still depends on broader clinical validation. For now, QTTB's improved financing gives them room to maneuver in the short term, which helps de-risk the stock as well. That means QTTB's subsequent updates by 2H2026, 1H2027, and 2H2027 are what will ultimately make or break my bull case on the stock.

-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata -- WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA will be featured across late-breaking oral and poster presentations at the European Academy of Dermatology and Venereology ("EADV") Congress, taking place September 30 – October 3, 2026 in Vienna, Austria.

Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript